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Pregnancy Outcomes in
Women With Dilated Cardiomyopathy
Jasmine Grewal, MD,* Samuel C. Siu, MD, SM,*† Heather J. Ross, MD,‡ Jennifer Mason, RN,*
Olga H. Balint, MD,* Mathew Sermer, MD,* Jack M. Colman, MD,* Candice K. Silversides, MD, SM*
Toronto and London, Ontario, Canada
Objectives The objectives of this study were to determine adverse outcomes during pregnancy in women with dilated car-
diomyopathy (DCM) and to compare their cardiac outcomes with those of nonpregnant women with DCM.
Background Women with DCM are at risk for complications during pregnancy, but few studies have examined outcomes in
this specific population.
Methods This was a substudy of a larger prospective cohort study of outcomes in women with heart disease. Maternal
cardiac, obstetric, and fetal outcomes in pregnancy in women with DCM were examined. For comparison, car-
diac outcomes in nonpregnant women with DCM (n  18) matched by age and left ventricular (LV) systolic func-
tion were examined. A matched-pair survival analysis was used to compare groups.
Results Thirty-six pregnancies in 32 women with DCM were included. Thirty-nine percent (14 of 36) of the pregnancies
were complicated by at least 1 maternal cardiac event. In the multivariate analysis, moderate or severe LV dys-
function and/or New York Heart Association functional class III or IV (p  0.003) were the main determinants of
adverse maternal cardiac outcomes during pregnancy. In the subset of women with moderate/severe LV dys-
function, 16-month event-free survival was worse in pregnant women compared with nonpregnant women
(28  11% vs. 83  10%, p  0.02). The adverse neonatal event rate was highest among women with obstetric
and cardiac risk factors (43%).
Conclusions In pregnant women with DCM the risk of adverse cardiac events is considerable, and pre-pregnancy characteris-
tics can identify women at the highest risk. Pregnancy seems to have a short-term negative impact on the clini-
cal course in women with DCM. (J Am Coll Cardiol 2010;55:45–52) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.036g
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iomen with dilated cardiomyopathy (DCM) are at risk for
omplications during pregnancy if they are unable to adapt
o the hemodynamic changes of pregnancy. In the Confi-
ential Enquiries into Maternal Death in the United King-
om, maternal cardiac deaths during pregnancy, although
are, were frequently related to ventricular dysfunction (1).
owever, little is known about cardiac morbidity or risk
tratification in this population. Although the literature
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ccepted August 10, 2009.enerally advises against pregnancy in women with signifi-
ant left ventricular (LV) systolic dysfunction (left ventric-
lar ejection fraction [LVEF] 30%), there are minimal
ata to support this recommendation (2). Counseling about
he safety of pregnancy can have a major impact on
rospective mothers, and it is therefore important that more
ata be available to help provide appropriate advice about
regnancy risks to women with a DCM. Therefore, the
urposes of this study were: 1) to examine adverse maternal
ardiac, obstetric, and fetal and/or neonatal events in a
ontemporary group of women with DCM undergoing
regnancy; and 2) to determine the impact of the pregnancy
n the clinical course of the disease by comparing adverse
ardiac events in pregnant versus nonpregnant women with
CM and significant LV systolic dysfunction.
ethods
tudy population. Women with previously documented id-
opathic or doxorubicin-induced DCM were enrolled in our
ngoing prospective pregnancy outcomes study between De-
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A DCM was defined as a dilated
ventricle with reduced LVEF in
the absence of coronary, valvular,
congenital, or any systemic dis-
eases known to cause myocardial
dysfunction (5). Women with car-
diomyopathies from other causes,
including peripartum cardiomyo-
pathy, were excluded. Peripartum
cardiomyopathy was defined by:
1) the development of heart failure
n the last month of pregnancy or within 5 months of delivery;
) an LVEF 45% by echocardiography; 3) absence of an
dentifiable cause for the cardiac failure; and 4) absence of
ecognizable heart disease before the last month of pregnancy.
onpregnant women were matched with pregnant women by
ge, diagnosis, degree of LV systolic dysfunction, and year of
regnancy (year of initial clinic visit) and followed up over 16
onths to ascertain event rates. For the purpose of this
omparison, only women with moderate or severe LV dysfunc-
ion (LVEF 45%) were included. This study received insti-
utional ethics approval.
aseline data and follow-up. Details pertaining to data
ollection in women with heart disease followed up in our
regnancy and Heart Disease Research Program at Univer-
ity Health Network and Mount Sinai Hospitals have been
escribed elsewhere (3). All pregnant women were followed
p prospectively from the start of pregnancy until 6 months
ost-partum. Clinical, electrocardiographic, and echocar-
iographic data were collected at the time of clinic visits.
hese baseline data were recorded: age, comorbid medical
onditions (pulmonary disease, thyroid dysfunction, hyper-
ension, diabetes mellitus), smoking history, New York
eart Association (NYHA) functional class, prior cardiac
vents (heart failure, transient ischemic attack, arrhythmias,
r stroke), prior cardiac interventions, use of cardiac medi-
ations, and anticoagulation. In the group of pregnant
omen, these additional baseline data were recorded: ges-
ational age and parity status. Medication use was recorded
t the time of the first antenatal visit among pregnant
omen. In many instances, cardiac medications recorded at
he first antenatal visit were not representative of the
edications used before pregnancy because medications
uch as angiotensin-converting enzyme inhibitors had al-
eady been discontinued by an alternate care provider or
ere stopped before conception. Obstetric risk factors
ssociated with adverse fetal and/or neonatal events were
lso recorded for the pregnant group of women and in-
luded history of premature delivery or rupture of mem-
ranes, incompetent cervix, and cesarean section, and dur-
ng the present pregnancy included intrauterine growth
etardation, antepartum bleeding 12 weeks gestation,
ebrile illness, or uterine/placental abnormalities (3,6–9).
Echocardiographic assessment included left and right ven-
Abbreviations
and Acronyms
DCM  dilated
cardiomyopathy
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationricular systolic function, valvular function, and systolic pulmo- tary artery pressure (4,10). Left ventricular systolic function
as given a functional grade assessment: normal (LVEF
55%), mild (45% to 54%), moderate (30% to 44%), or severe
30%) (11). The modified Quinones method was used to
alculate LVEF (12), with subsequent visual estimation if
ndocardial definition was suboptimal. An experienced echo-
ardiographer interpreted all echocardiograms.
Nonpregnant and pregnant women were followed up for
n equal length of time (16 months). The beginning of
ollow-up in the nonpregnant group was at the time of their
rst visit to the heart failure clinic at our institution.
aseline clinical, electrocardiographic, and echocardio-
raphic data as described earlier were recorded. Medication
se at the time of first heart failure clinic visit was recorded.
utcomes. Adverse events during the antepartum, peri-
artum, and post-partum periods were classified as cardiac,
etal and/or neonatal, and obstetric. Two physicians blinded
o the women’s baseline characteristics independently veri-
ed adverse events. Adverse cardiac events for both preg-
ant women and nonpregnant control subjects were defined
s pulmonary edema (documented by chest radiograph or by
rackles heard over at least one-third of posterior lung
elds); sustained symptomatic tachyarrhythmia or brady-
rrhythmia requiring treatment; stroke, angina, or myocardial
nfarction; cardiac arrest; or cardiac death. Fetal and neonatal
omplications were defined as premature birth (37 weeks
estation), small-for-gestational-age birth weight (10th per-
entile for gestational age), respiratory distress syndrome,
ntraventricular hemorrhage, fetal death (20 weeks gestation
nd before birth), or neonatal death (from birth to age 28 days).
bstetric complications were maternal death from noncardiac
auses, pregnancy-induced hypertension (increase of 30 mm
g in systolic blood pressure and 15 mm Hg in diastolic blood
ressure compared with baseline values), or post-partum hem-
rrhage (blood loss 500 ml after vaginal delivery or 1,000
l after cesarean section, requiring transfusion or accompanied
y a decrease in hemoglobin level 20 g/l).
tatistics. All data were analyzed using SPSS version 16.0
SPSS Inc., Chicago, Illinois). Data are presented as median
alue with interquartile range, and in some instances ranges
re also provided. Univariate predictors of maternal cardiac
omplications during pregnancy in women with DCM were
etermined using univariate logistic regression analysis. A
ultivariate logistic regression model was then created to
dentify predictors of adverse maternal cardiac events during
regnancy based on the univariate analysis. Variables iden-
ified in the univariate analysis with a value of p  0.1 were
ncluded in the multivariate model. Because of the correla-
ion between NYHA functional class and LV systolic
unction, a single variable was created for the multivariate
odel combining NYHA functional class III or IV and
oderate or severe LV dysfunction.
The second analysis consisted of a comparison of outcomes
n pregnant versus nonpregnant women with DCM and
oderate or severe LV systolic dysfunction. Baseline charac-eristics between groups were determined using McNemar or
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vents in pregnant women were compared with those in
onpregnant women. Survival in both groups was depicted
sing Kaplan-Meier curves, and comparison between
roups was performed using a matched-pair survival analy-
is. A value of p 0.05 (2-sided) was considered statistically
ignificant.
esults
etween December 1994 and July 2008, 906 women with
eart disease undergoing pregnancy were prospectively fol-
owed up and enrolled in our larger cohort study. Of these,
6 pregnancies occurred in women with DCM (32 women);
4% (n  27) with idiopathic DCM and 16% (n  5) with
oxorubicin-induced cardiomyopathy. Baseline characteris-
ics of pregnant women and control subjects are summarized
n Table 1. Of the 4 women who had an episode of heart
ailure before pregnancy, 2 had mild, 1 had moderate, and 1
ad severe LV systolic dysfunction at the time of enrollment.
ne woman with severe LV dysfunction had an implantable
ardioverter-defibrillator implantation. Her ventricular func-
ion had improved before pregnancy, and the lead was subse-
uently explanted because of a manufacturer’s recall. At the
ime of post-partum discharge, 3 (9%) women were in NYHA
unctional class II, 1 (3%) was in class IV, and the remainder
ere in class I.
aternal cardiac outcomes. Fourteen of 36 (39%) preg-
ancies (up to 6 months post-partum) in women with a
CM were complicated by at least 1 adverse maternal
ardiac event (Table 2). One woman experienced heart
ailure at 13 weeks gestation followed by nonsustained
entricular tachycardia at 15 weeks gestation, necessitating a
herapeutic abortion. Twenty-four weeks after the proce-
ure she presented again with ventricular tachycardia. Atrial
brillation or flutter occurred in 4 women during the
ntepartum period (17, 23, 28, and 36 weeks gestation), and
n 1 woman during labor and delivery. Heart failure oc-
urred in 3 pregnancies during the antepartum period (20,
8, and 38 weeks gestation), 1 during labor and delivery,
nd 4 during the post-partum period (2 days, 5 days, 12
eeks, and 16 weeks after delivery). A transient ischemic
ttack occurred in 1 woman at 19 weeks gestation. All
dverse maternal cardiac events were successfully managed
ith medical therapy.
Characteristics predictive of an adverse cardiac event during
regnancy in univariate analysis are shown in Table 3. In
ultivariate analysis, moderate or severe LV systolic dys-
unction and/or NYHA functional class III or IV were the
ain determinants of adverse maternal cardiac events dur-
ng pregnancy (Table 3). A history of cardiac events before
regnancy showed a trend toward significance for predicting
regnancy-related maternal cardiac outcomes. After exclud-
ng multiple pregnancies in the same individual, the univar-
ate and multivariate analyses were repeated (n 4), and the
esults remained unchanged. NThe frequency of adverse maternal cardiac events over the
6-month follow-up varied according to the severity of LV
ystolic dysfunction. Only 1 woman with mild LV systolic
ysfunction and in baseline NYHA functional class II had
n adverse cardiac event; however, she also had a history of
ardiac events before pregnancy. The frequency of adverse
ardiac events was similar between women with moderate or
evere LV systolic dysfunction (75% [6 of 8] moderate and
0% [7 of 10] severe, p  0.81). All women with moderate
V systolic dysfunction also had 1 other high-risk charac-
eristic; 50% (4 of 8) had a prior cardiac event, 25% (2 of 8)
ere NYHA functional class III or IV, and 25% (2 of 8) had
oderate or severe mitral regurgitation.
All women with adverse cardiac events during pregnancy
n  14) had either moderate or severe LV dysfunction,
aseline Characteristics of Pregnant Women (n  36)Table 1 Baseline Characteristics of Pregnant Women (n  36)
Clinical
Pregnancies 36
Women 32
Nulliparity 16 (44)
Age at enrollment, yrs 32 (27–35)
Other cardiac defects
Secundum ASD* 3 (8)
MVP (mild MR) 3 (8)
History of cardiovascular events
Heart failure 4 (11)
Transient ischemic attack 1 (3)
Supraventricular tachycardia 2 (6)
Atrial fibrillation/flutter 2 (6)
Other medical conditions
Hypertension 3 (8)
Hyperlipidemia 1 (3)
Smoking history 4 (11)
Epilepsy 1 (3)
Cancer† 5 (14)
Prior cardiac intervention 1 (3)
NYHA functional class
I 24 (67)
II 6 (17)
III or IV 6 (17)
Cardiac medications at first antenatal visit
ACE inhibitors 4 (11)
Beta-blockers 13 (36)
Digoxin 8 (22)
Diuretic 7 (19)
Echocardiographic
Left ventricular systolic dysfunction
Mild 18 (50)
Moderate 8 (22)
Severe 10 (28)
Moderate/severe MR 10 (28)
Moderate/severe TR 7 (19)
ata are n, n (%), or median (interquartile range). *The atrial shunt was classified as small by color
oppler and the absence of right ventricular dilation in all 3 patients. †Breast cancer in 2 patients,
eukemia in 2 patients, and Wilms tumor in 1 patient.
ACE  angiotensin-converting enzyme; ASD  atrial septal defect; MR  mitral regurgitation;
VP  mitral valve prolapse; NYHA  New York Heart Association; TR  tricuspid regurgitation.YHA functional class III or IV, and/or a previous cardiac
e
t
t
c
r
O
c
p
w
g
w
1
a
p
i
r
c
d
m
p
l
r
T
n
b
w
t
n
F
f
f
i
o
c
a
f
b
0
p
s
g
1
w
d
h
C
n
f
p
w
c
by 1 or
P
V
48 Grewal et al. JACC Vol. 55, No. 1, 2010
Dilated Cardiomyopathy and Pregnancy December 29, 2009/January 5, 2010:45–52vent. There were no adverse events in women with none of
hese 3 clinical parameters (moderate or severe LV dysfunc-
ion, NYHA functional class III or IV, and/or a previous
ardiac event). If any 1 of these 3 risk factors was present, the
isk of an adverse cardiac event was 64% (14 of 22) (Fig. 1).
bstetric and fetal/neonatal outcomes. The 36 pregnan-
ies resulted in 37 live births, including 1 twin and 1 triplet
regnancy (Table 4). There was 1 therapeutic abortion at 20
eeks and 1 fetal death. Among the live births, the median
estational age at delivery was 38 weeks (range 28 to 41
eeks), and the median birth weight was 3,060 g (range
,230 to 4,045 g). The most frequently used method of
nesthesia was an epidural in 86% of deliveries. Eighty-one
ercent (29 of 36) of the deliveries were vaginal, and were
nduced in 11% of cases. Cesarean deliveries occurred in the
emaining 7 pregnancies for these indications: previous
esarean delivery (n  3), failure to progress (n  1), fetal
istress (n 1), breech presentation (n 1), and coexistent
edical condition (n  1). Cesarean delivery was not
erformed for cardiac indications in any of the women. The
ength of hospital stay was a median of 3 days (interquartile
ange 3 to 6 days). Adverse obstetric outcomes are shown in
able 4.
Seven of 35 (20%) pregnancies (not including the preg-
ancy that ended in therapeutic abortion) were complicated
y an adverse fetal and/or neonatal event (Table 4). Even
Maternal Adverse Cardiovascular Outcomes DurTable 2 Maternal Adverse Cardiovascular O
Any Cardiac
Event
Cardiac Arr
or Death
Total 17 0
Timing of events
Antepartum 10 0
Labor and delivery 2 0
Post-partum (6 months) 5 0
Events are not mutually exclusive. Fourteen pregnancies complicated
MI  myocardial infarction; TIA  transient ischemic attack.
redictors of Adverse Cardiac Events in Pregnant Women With DilaTable 3 Predictors of Adverse Cardiac Events in Pregnant Wom
Adv
Univariate analysis
Age, yrs
Nulliparity
Prior adverse cardiac events
Baseline NYHA functional class III or IV
Moderate or severe LV systolic dysfunction
Severe mitral regurgitation
Severe tricuspid regurgitation
Comorbid medical conditions
Moderate or severe LV dysfunction and/or NYHA functional class III or IV
Multivariate analysis
Moderate or severe LV dysfunction and/or NYHA functional class III or IV
Prior adverse cardiac eventsalues are median (interquartile range) or n (%).
CI  confidence interval; LV  left ventricle; NYHA  New York Heart Association; OR  odds ratio.hen the 2 multiple-gestation pregnancies (1 twin and 1
riplet) were excluded from the analysis, the fetal and/or
eonatal event rate remained high at 15% (5 of 33).
ifty-three percent (19 of 36) of women had at least 1 risk
actor for adverse fetal and/or neonatal events. Obstetric risk
actors associated with adverse fetal and/or neonatal events
ncluded any prior history of premature delivery or rupture
f membranes (n  1), incompetent cervix (n  0), or
esarean deliveries (n  2). During the current pregnancy,
ny of these variables was also considered an obstetric risk
actor: intrauterine growth retardation (n  1), antepartum
leeding 12 weeks gestation (n  1), febrile illness (n 
), or uterine/placental abnormalities during the present
regnancy (n  3). Nonobstetric risk factors included
moking (n  4), anticoagulation use (n  3), multiple
estation (n  2), and maternal age 20 or 35 years (n 
1). Neonatal complications were most common in women
ith more severe DCM (moderate or severe LV systolic
ysfunction and/or NYHA functional class III or IV) if they
ad concomitant obstetric risk factors (Fig. 2).
omparisons of cardiac outcomes in pregnant versus
onpregnant women with significant LV systolic dys-
unction. Because the 16-month event rate was low among
regnant women with mild LV systolic dysfunction, these
omen were not included in this analysis. The baseline
haracteristics of the 18 nonpregnant women and 18 preg-
regnancyes During Pregnancy
Heart Failure Arrhythmia Stroke/TIA
Angina
or MI
9 7 1 0
4 5 1 0
1 1 0 0
4 1 0 0
more event.
ardiomyopathyith Dilated Cardiomyopathy
ardiac Event
14)
No Adverse Cardiac Events
(n  22) OR (95% CI) p Value
24–36) 31 (29–35) 1.0 (0.9–1.1) 0.98
43) 10 (45) 1.1 (0.3–4.3) 0.88
43) 3 (14) 4.7 (1.1–23.8) 0.05
36) 1 (4) 11.7 (1.2–114.6) 0.03
86) 5 (23) 44.2 (4.6–421.2) 0.001
36) 1 (5) 11.7 (1.2–114.6) 0.04
29) 3 (14) 2.5 (0.4–13.6) 0.28
36) 10 (45) 0.67 (0.17–2.6) 0.56
93) 6 (27) 16.0 (2.7–93.6) 0.0001
42.6 (3.5–517.1) 0.003
7.0 (0.6–78.8) 0.08ing Putcom
estted Cen W
erse C
(n 
34 (
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ysfunction are shown in Table 5. Significantly more
onpregnant women were taking cardiac medications dur-
ng the 16-month follow-up period when compared with
he pregnant women. Three nonpregnant women (17%)
ad events during the 16-month follow-up period: cardiac
ransplantation caused by refractory heart failure (n  1),
eath secondary to ventricular tachycardia (n  1), and
yncope secondary to ventricular tachycardia (n  1). In
omen with moderate or severe LV systolic dysfunction,
dverse cardiac events were more common in pregnant
omen compared with nonpregnant women with a DCM
Figure 1 Incidence of Adverse Cardiac
Events According to Maternal Risk Factors
The first 3 risk categories are not mutually exclusive. Any risk factor refers to
the presence of any 1 of the 3 risk factors (moderate or severe left ventricular
[LV] dysfunction, New York Heart Association [NYHA] functional class III or IV,
previous cardiac events).
bstetric and Fetal OutcomesTable 4 Obstetric and Fetal Outcomes
Pregnancies, n (%)
Adverse obstetric outcomes
Total events* 5/36 (14)
Pre-eclampsia 3 (8)
Post-partum hemorrhage 2 (5)
Noncardiac death 0 (0)
Adverse fetal outcomes
Total events† 7/35 (20)
Live birth weight 2,500 g 5 (14)
Pre-term delivery (37 weeks) 5 (14)
Intraventricular hemorrhage 0 (0)
Respiratory distress 1 (3)
Fetal death‡ 1 (3)
Neonatal death 0 (0)
Intrauterine growth retardation 1 (2)
Percentage of total 36 pregnancies that had an obstetric complication. †Percentage of 35
regnancies that had a neonatal complication (36 pregnancies minus the therapeutic abortion).
ach twin and triplet pregnancy was counted as a single pregnancy: the twins and triplets all had
ow birth weight (2,500 g), and the triplets were also premature (37 weeks). ‡Occurred at 28
eeks of gestation in a woman who developed pulmonary edema.
n72% [13 of 18] vs. 17% [3 of 18]). The 16-month
vent-free survival was worse in pregnant women compared
ith nonpregnant women (28  11% vs. 83  10%, p 
.02) (Fig. 3).
0/12=0% 0/4=0%
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6/14=43%
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No Risk Factor    Risk Factors
Mild LV systolic dysfunction and NYHA I/II
Moderate/severe LV systolic dysfunction
and/or NYHA III/IV
Figure 2 Frequency of Neonatal Events in
Women With and Without Risk Factors
Yellow bars represent women with both mild LV systolic dysfunction and NYHA
functional class I or II. Green bars represent women with moderate or severe
LV systolic dysfunction and/or NYHA functional class III or IV. Risk factors of
adverse fetal and/or neonatal events included both obstetric and nonobstetric
parameters. Obstetric risk factors include a history of premature delivery or
rupture of membranes, incompetent cervix, cesarean delivery, and during the
present pregnancy, intrauterine growth retardation, antepartum bleeding 12
weeks gestation, febrile illness, and uterine/placental abnormalities. Nonob-
stetric risk factors include smoking, anticoagulation use, multiple gestation,
and maternal age 20 and 35 years. Abbreviations as in Figure 1.
haracteristics of Pregnant Womenompar d With Nonpregnant WomenTable 5 C aracteristics of Pr g ant WomenCompared With Nonpregnant Women
Pregnant
Women
(n  18)
Nonpregnant
Women
(n  18) p Value
Clinical
Nulliparity 8 (44) 18 (100) 0.002
Age at enrollment, yrs 32 (20–35) 35 (26–38) 0.15
Other medical conditions
Hypertension 2 (11) 1 (6) 1.0
Smoking history 2 (11) 1 (6) 1.0
Hyperlipidemia 1 (5) 1 (6) 0.48
NYHA functional class III or IV 5 (28) 7 (39) 0.14
Moderate to severe LV dysfunction 18 (100) 18 (100) 1.0
Moderate dysfunction 10 10
Severe dysfunction 8 8
Cardiac medications*
Any cardiac medication 11 (61) 18 (100) 0.02
ACE inhibitors 2 (11) 17 (94) 0.0001
Beta-blockers 6 (33) 16 (89) 0.006
Digoxin 7 (39) 7 (39) 1.0
Diuretic 3 (17) 12 (67) 0.004
alues are n (%) or median (interquartile range). *Cardiac medications recorded at the first
ntenatal visit among pregnant women and at the time of the first heart failure clinic visit among
onpregnant women.
ACE angiotensin-converting enzyme; LV left ventricle; NYHA New York Heart Association.
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his is the first study to examine in detail the risks of
regnancy in women with DCM. In this cohort of pregnant
omen with DCM, we found that maternal cardiac com-
lications were considerable in women with moderate or
evere LV systolic dysfunction and/or NYHA functional
lass III or IV symptoms. In our study, women with no
istory of cardiac events, mild LV systolic dysfunction, and
ood functional class did well and did not have any cardiac
omplications during pregnancy. Adverse fetal and/or neo-
atal events were highest in women with moderate or severe
V systolic dysfunction and/or NYHA functional class III
r IV if they had concomitant obstetric risk factors. Preg-
ancy seemed to have a negative impact on the clinical
ourse of DCM because adverse cardiac events were more
ommon over a 16-month period in pregnant women
ompared with nonpregnant women with DCM.
Cardiac complications during pregnancy in our series
ere high (39% of pregnancies). The most common com-
lication was heart failure, and this typically occurred late in
he pregnancy or post-partum. In 1 small prior retrospective
eries of women with DCM (8 women), 25% of pregnancies
ere complicated by adverse events; 1 woman with an
VEF of 16% required transplantation after termination of
regnancy, and in another, heart failure developed at 28
eeks of gestation (13). However, 50% of the women (4 of
Figure 3 Comparisons of Cardiac Outcomes in Pregnant Versus Non
Sixteen-month survival free from adverse cardiac events in pregnant women (dash
Time zero is defined as: 1) the first antenatal visit for pregnant women; and 2) the) had only mild LV systolic dysfunction. In another larger ieries of women with heart disease (43 women with cardio-
yopathy, 18 with idiopathic DCM), adverse events oc-
urred in 42% of pregnancies in the subset of patients with
ardiomyopathy. However, the specific event rate in women
ith DCM was not reported (10). Furthermore, there were
maternal deaths in the cardiomyopathy group, but again it
as not reported whether any of these deaths occurred in
he setting of DCM. In our series, despite the high risk of
omplications in this group of women, all complications
ere successfully managed with medical therapy and there
ere no maternal deaths. This is a reassuring experience, but
ertainly maternal mortality is possible in high-risk women
ith DCM, and this possibility needs to be considered
hen counseling an individual. Furthermore, the late effects
f pregnancy on the diseased heart are not well understood,
nd the effects on long-term ventricular function and
rognosis require further study.
A number of prior studies have identified risk factors for
dverse maternal outcomes during pregnancy, including
YHA functional class (4,14). Independent of functional
tatus, LVEF 40% also has been shown to predict adverse
vents in pregnancy (4,14,15). Our findings in women with
CM are similar, although it is important to note that only
small number of women were in NYHA functional class
II or IV in our study. The rate of adverse maternal cardiac
vents is high in this group of women, and approaches 65%
ant Women With Significant Left Ventricular Systolic Dysfunction
) compared with nonpregnant women (solid line).
visit to the heart failure clinic for nonpregnant women.pregn
ed line
indexf one or more of these risk factors were present: moderate
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December 29, 2009/January 5, 2010:45–52 Dilated Cardiomyopathy and Pregnancyr severe LV systolic dysfunction, NYHA functional class
II or IV, and/or a history of an adverse cardiac event.
lternatively, if none of these factors were present, women
id not experience adverse events. These disease-specific
ndings are incremental to previous work and will be
mportant in the counseling and follow-up during preg-
ancy in women with DCM.
Results of this study also show that pregnancy in women
ith DCM directly impacts the natural course of the
isease, at least over the short term. We showed that cardiac
omplications in pregnant women were significantly more
ommon compared with those in nonpregnant women
uring a 16-month follow-up period. The increased inci-
ence of adverse cardiac events among pregnant women
eems to begin in the third trimester at the time of maximal
emodynamic change, supporting the idea that it is the
emodynamic load that leads to cardiac decompensation.
ome studies have shown a transient decrease in LV
ontractility during pregnancy (16), and this may also play a
ole in cardiac decompensation in women with abnormal
V function. Although many of the baseline characteristics
ere similar between the 2 groups, the authors acknowledge
hat an important difference between groups was that non-
regnant women were more likely to receive angiotensin-
onverting enzyme inhibitors, beta-blockers, and diuretic
gents over the 16-month follow-up when compared with
heir pregnant counterparts. Although many pregnant
omen were optimally managed on heart failure therapy
efore pregnancy, medications were discontinued early in
regnancy because of contraindications and/or patient pref-
rence. This factor may also explain some of the observed
ifferences in event rates between the 2 groups. In addition
o increased cardiac complications during pregnancy, dis-
ontinuing cardiac medications for the duration of preg-
ancy may also have late negative effects on ventricular
unction.
In the population of pregnant women with DCM described
n this study, we observed a high rate (20%) of adverse fetal
nd/or neonatal events. Previous studies examining pregnant
omen with other forms of heart disease have also reported
igh rates of neonatal complications (14,15,17–21). Specifi-
ally, in a prospective study from our center of neonatal
utcomes in pregnant women with all forms of heart disease,
dverse neonatal outcomes occurred in 18% of pregnancies in
he heart disease group, compared with 7% of healthy pregnant
ontrol subjects (2). Previous work and this study showed that
hese complications are more common in women with ad-
anced LV dysfunction and poor functional class (3). In
ddition, we found there to be an important interaction
etween maternal cardiac and obstetric risk factors and fetal
nd/or neonatal outcomes (2). Fetal and/or neonatal event
ccurrences were high in women with moderate or severe LV
ystolic dysfunction and/or NYHA functional class III or IV if
here were concomitant obstetric risk factors. The mechanism
or this finding is not known and requires further study.
inally, although many risk factors cannot be modifiable, thosehat can, such as smoking, could certainly be addressed in an
ttempt to reduce the risk of fetal complications.
tudy limitations. Because all women included in this pro-
pective study were receiving care at a tertiary care cardiac
enter, a referral bias may exist. Women with less severe heart
isease or those doing well during pregnancy may not have
een referred to our center. However, a substantial proportion
f women had only mild LV dysfunction, suggesting that
ilder forms of disease were indeed included in the cohort.
ecause of the small sample size, this study was not powered to
dentify multiple predictors of outcomes. Larger sample sizes
ould be needed to identify additional determinants of out-
ome. Newer echocardiographic measures of ventricular func-
ion and mechanics as well as serum markers such as brain
atriuretic peptide were not obtained, but may serve as useful
rognostic markers in the future. Longer-term follow-up was
ot the focus of this study, but would be valuable in under-
tanding the long-term effects of pregnancy on the diseased
eart.
onclusions
n pregnant women with DCM, clinical parameters, includ-
ng NYHA functional class and LV systolic function, can be
sed to identify women at highest risk for cardiac compli-
ations during pregnancy. When compared with nonpreg-
ant women, pregnancy seems to have a negative impact on
he clinical course for women with DCM, at least over the
hort term. Fetal and/or neonatal complications are also
ncreased in mothers with DCM, and the risk is magnified
y the presence of both cardiac and obstetric risk factors.
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